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The sympathetic nervous system (SNS) is known to play a pivotal role in short- and
long-term regulation of different functions of the cardiovascular system. In the past
decades increasing evidence demonstrated that sympathetic neural control is involved
not only in the vasomotor control of small resistance arteries but also in modulation of
large artery function. Sympathetic activity and vascular function, both of which are key
factors in the development and prognosis of cardiovascular events and disease, are linked
at several levels. Evidence from experimental studies indicates that the SNS is critically
influenced, at the central and also at the peripheral level, by the most relevant factors
regulating vascular function, such as nitric oxide (NO), reactive oxygen species (ROS),
endothelin (ET), the renin-angiotensin system. Additionally, there is indirect evidence of a
reciprocal relationship between endothelial function and activity of the SNS. A number of
cardiovascular risk factors and diseases are characterized both by increased sympathetic
outflow and decreased endothelial function. In healthy subjects, muscle sympathetic
nerve activity (MSNA) appears to be related to surrogate markers of endothelial function,
and an acute increase in sympathetic activity has been associated with a decrease
in endothelial function in healthy subjects. However, direct evidence of a cause-effect
relationship from human studies is scanty. In humans large artery stiffness has been
associated with increased sympathetic discharge, both in healthy subjects and in renal
transplant recipients. Peripheral sympathetic discharge is also able to modulate wave
reflection. On the other hand, large artery stiffness can interfere with autonomic regulation
by impairing carotid baroreflex sensitivity.
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INTRODUCTION
The sympathetic nervous system (SNS), one of the two divisions
of the autonomic nervous system, is known to play a central
role in cardiovascular homeostasis (Wallin and Charkoudian,
2007). In particular, SNS is the effector of neurogenic control of
vascular tone, inducing mainly vasoconstriction of small resis-
tance arteries. It is well established that SNS is mainly involved
in short-term regulation of vasomotor tone and blood pressure
(BP), allowing fast adaptation to different physiological condi-
tions by means of the classical autonomic reflexes, in order to
maintain cardiovascular homeostasis (Wallin and Charkoudian,
2007). Increasing evidence suggests that sympathetic activity also
plays a key role in long-term BP control (Joyner et al., 2008; Fink,
2009). Experimental studies demonstrated that sympathetic acti-
vation may induce sustained BP increases by several mechanisms
(Joyner et al., 2008; Fink, 2009; Grassi, 2009). In the last few years,
novel non-pharmacological antihypertensive approaches target-
ing SNS have been developed in humans, including renal denerva-
tion and baroreceptor-activating therapy, highlighting the clinical
relevance of autonomic modulation of BP (Unger et al., 2011).
Recent indirect and direct evidence suggests that sympathetic
activity and vascular function, which are both key factors in the
development and prognosis of cardiovascular events and disease,
could be linked in a more complex fashion. In particular, the
same pathways are involved in central and peripheral autonomic
regulation as well as in vascular function regulation, suggesting
that vascular homeostasis is maintained through pathways acti-
vated by the same signaling both at the level of the autonomic
nervous system and in the vascular milieu, allowing an inte-
grated, multidistrict response (Grassi, 2001; Patel et al., 2001;
Bruno et al., 2011; Hirooka et al., 2011). Furthermore, SNS
may directly modulate functional and mechanical properties of
large arteries. This is suggested by the evidence that markers of
vascular function are inversely related to various measures of
sympathetic discharge (Sverrisdottir et al., 2010; Swierblewska
et al., 2010), and it is in line with the induction of endothe-
lial dysfunction by sympatho-excitatory maneuvers (Padilla et al.,
2010). Adrenergic activation is also chronically present in sev-
eral cardiovascular diseases: this represents a detrimental and
maladaptive phenomenon, possibly inducing chronic changes
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in vascular function and structure, namely vascular remodeling
(Grassi et al., 2009). Moreover, chronic adrenergic hyperactivity
is involved in the pathogenesis of several cardiovascular risk fac-
tors, thus indirectly inducing vascular dysfunction and damage
(Lembo et al., 1992; Joyner et al., 2008). Sympathetic activity may
induce sustained increases in BP through several mechanisms,
e.g., by causing peripheral vasoconstriction, potentiating cardiac
contraction, reducing venous capacitance, affecting renal sodium,
and water excretion, through baroreflex dysfunction (Fink, 2009).
A higher sympathetic tone could also favor weight gain, hyperin-
sulinemia and altered glucose metabolism (Lembo et al., 1992;
Joyner et al., 2008), all of which are conditions heavily compro-
mising vascular function and structure. Microneurography is a
technique allowing direct recording of sympathetic efferent post-
ganglionic discharge directed to various different districts (Grassi
and Esler, 1999). In particular it is used to record from a periph-
eral nerve the sympathetic discharge controlling vasomotor tone
in muscle vascular districts in humans, the so-called muscle sym-
pathetic nerve activity (MSNA) (Grassi and Esler, 1999). Though
limited by technical difficulty and by invasiveness, microneurog-
raphy has many advantages: it is highly reproducible over several
years, it is closely related to sympathetic traffic directed to other
districts such as the brain, heart, and kidney, it can be repeated
over time to assess effects of interventions, it allows direct quan-
tification of sympathetic nerve traffic regulating vasomotor tone
and study of instantaneous reactions to rapid stimuli (Vallbo
et al., 2004). For these reasons, it is an irreplaceable tool in order
to comprehend physiological mechanisms underlying autonomic
reflexes and to reveal relationships between peripheral neural
activity and various functions, including vascular function.
This review is aimed at evaluating the state-of-the art on the
sympathetic regulation of vascular function in health and dis-
ease. In particular, the relationship with endothelial dysfunction,
which is an alteration specifically due to reduced nitric oxide
(NO) bioavailability in endothelial cells, and arterial stiffness,
a process with both a functional and structural basis occurring
mainly in large arteries and critically influenced by endothelium-
derived substances, is explored. Evidence derived from experi-
mental animal studies, including microneurographic studies, is
reviewed for the section regarding common regulating pathways
between SNS and vascular function. The subsequent sections
are mainly focused on human studies performed by means of
microneurography, although studies performed with different
techniques are also quoted whenever appropriate.
SNS AND VASCULAR FUNCTION: COMMON REGULATING
PATHWAYS
Evidence from experimental studies indicates that the SNS is crit-
ically influenced, both at the central and peripheral level, by the
most relevant factors regulating vascular function: NO, reactive
oxygen species (ROS), endothelin (ET), the renin-angiotensin
system (Figure 1).
NITRIC OXIDE
NO is probably the most important molecule produced by the
endothelium. NO is produced from the aminoacid L-arginine
FIGURE 1 | Diagram illustrating interrelationships between the
sympathetic nervous system (SNS) and vascular function. SNS
influences vascular function through multiple mechanisms, including direct
vasoconstriction and wall remodeling, blood pressure increase, and
metabolic alterations. In turn, arterial stiffness seems to induce baroreflex
impairment, thus altering SNS regulation. Furthermore, the same regulatory
systems are involved in vascular and SNS homeostasis, with beneficial (in
green) and detrimental (in red) effects.
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by an enzyme known as NO synthase (NOS), which is present
in three isoforms in different tissues (Luscher and Vanhoutte,
1990; Bruno and Taddei, 2011). Neuronal NOS (nNOS) is con-
stitutively expressed in neurons both in the central and in the
peripheral nervous system: NO is in effect an important neuro-
transmitter cooperating in autonomic regulation of cardiovas-
cular function (Patel et al., 2001; Hirooka et al., 2011). nNOS
is also present in macrophages and endothelial cells, where it
seems to play a role in regulation of basal vascular tone (Seddon
et al., 2008). Inducible NOS (iNOS) is expressed in a number
of different cellular types: its activity is negligible in baseline
conditions, but it is steadily induced by inflammatory stimuli
(Luscher and Vanhoutte, 1990). Endothelial NOS (eNOS) is a
constitutive enzyme isoform, first discovered in endothelial cells,
but also found in neuronal cells. NO release from endothelium
is determined by receptor-mediated mechanisms (acetylcholine,
bradikynin, serotonin, substance P, adenosine diphosphate), but
also by mechanical stimuli. In particular shear stress, namely tan-
gential cyclic stress generated on vascular walls by blood flow, is
the most powerful mechanism of stimulated NO release (Bruno
and Taddei, 2011). The main stimuli negatively influencing eNOS
expression are hypoxia, tumor necrosis factor-α, inflammatory
cytokines (Luscher and Vanhoutte, 1990). eNOS can be also
inhibited by false substrates such as N-monomethyl-L-arginine
(L-NMMA), which are commonly used to test the degree of
endothelium-dependent vasodilation. Asymmetric dimethylargi-
nine (ADMA), a naturally occurring aminoacid, is an endogenous
inhibitor of eNOS, which can cause endothelial dysfunction and is
associated with increased cardiovascular risk (Bruno and Taddei,
2011).
It is now well established that NO acts as a sympathoinhibitory
substance within the central nervous system (Patel et al., 2001).
This is demonstrated by several lines of evidence.
NOS activity (in particular nNOS) has been demonstrated in
central and peripheral sites involved in cardiovascular regula-
tion throughout the autonomic nervous system by histochem-
ical staining and immunohistochemistry (Bredt et al., 1990).
Furthermore, several experimental studies examined the central
effects of NO on sympathetic outflow by administration of NO
agonists or blockers orally, intravenously, intracerebroventricu-
larly, or into specific central sites (Patel et al., 2001; Hirooka
et al., 2011). The vasoconstrictor and BP-raising effect of acute
or chronic administration of exogenous NOS-inhibitors is well
established (Huang et al., 1994). This effect could be at least
in part due to vascular effects, namely impairment of NO
basal vascular tone and endothelium-mediated vasodilation, but
several experimental studies suggest that SNS activation may
play a key role in hypertensive response to NO-blockade (Patel
et al., 2001; Hirooka et al., 2011). Acute intravenous admin-
istration of NOS-inhibitors, such as L-NMMA, was found to
induce BP increase and SNS activation, measured by means
of serum norephinephrine assay and renal sympathetic nerve
activity (SNA) (Sakuma et al., 1992). Both responses were fur-
ther increased after baroceptor deafferentation and disappeared
after cervical spine section, suggesting that the L-NMMA pressor
effect is mostly due to its effect on SNS (Sakuma et al., 1992).
This conclusion is supported by the evidence that ganglionic
blockade (Cunha et al., 1993) and sympathectomy (Sander et al.,
1995) suppressed BP and heart rate increase induced by L-NAME
(another NOS-inhibitor). In contrast, few studies showed no
changes in BP or SNS activity after pharmacological NOS-
blockade (Liu et al., 1996).
Another confirmation of the putative dependency of hyper-
tension induced by NOS-blockade on action of the cen-
tral nervous system derives from experiments performed with
intracerebroventricular administration of L-NAME. Thus, its
hypertensive effect was blunted by β-blocker coadministration
(Nurminen et al., 1997) and by cervical spine section (Togashi
et al., 1992). Microinjection of NOS-inhibitors in the nucleus
tractus solitarius (NTS), the origin of vagal efferent fibers, caused
BP and renal SNA increase in rabbits undergoing or not undergo-
ing barodenervation (Harada et al., 1993). NOmodulation is also
particularly relevant in rostroventrolateral medulla (RVLM), the
main bulbar area of integration of excitatory autonomic efferent
fibers involved in cardiovascular regulation. Thus, microinjec-
tion of NOS-inhibitors at this level caused renal SNA and BP
increase, while NO-donors exhibited opposite effects (Zanzinger
et al., 1995). Furthermore, hypothalamic paraventricular nuclei
contain NOS-positive neurons, capable of modulating renal SNA
(Zhang et al., 1997).
NO seems also to play a role in the pathophysiology of diseases
characterized by increased sympathetic discharge. Experimental
hypertension is associated with reduced activity of the intrac-
erebral NO-pathway, as demonstrated in stroke-prone, sponta-
neously hypertensive rats, as well as in renovascular hypertensive
rats (Hirooka et al., 2011). The same phenomenon occurs in
experimental heart failure, which is characterized by decreased
nNOS expression in the central nervous system (Zucker, 2006).
NO seems to exert its regulatory functions in the SNS even
beyond the above-mentioned effects on central sympathetic
outflow. NOS has been localized in sympathetic nerves, gan-
glia, and adrenal glands of Sprague-Dawley rats and pigs, sug-
gesting that NO is released as a cotransmitter in the periph-
eral autonomic system (Dun et al., 1993; Modin et al., 1994).
The key role of nitrergic innervations of vascular smooth mus-
cle in neurogenic control of vascular function is reviewed in
greater detail elsewhere (Toda and Okamura, 2003). Moreover,
adrenergic receptors on endothelial cells, activated by circu-
lating norepinephrine, can stimulate NO release (Miller and
Vanhoutte, 1985). Finally, sympathetically-induced vasoconstric-
tion may increase shear stress on the vascular wall, which in turn
increases NO release from vascular endothelial cells. On the other
hand, NO may play a role in the adrenergic system by enhancing
the activity of norepinephrine neuronal reuptake in sympathetic
nerve terminals (Simaan and Sabra, 2011).
REACTIVE OXYGEN SPECIES
The half-life of NO, and therefore its biological activity, is crit-
ically influenced by the presence of ROS, such as superoxide.
This free radical rapidly reacts with NO to form the highly
reactive intermediate peroxynitrite (ONOO−). The formation
of nitroso-compounds has multiple negative effects, reducing
NO availability, exerting direct vasoconstrictor and cytotoxic
effects, and impairing the activity of the prostacyclin synthase and
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eNOS (Munzel et al., 2010). Other ROS, such as the dismutation
product of superoxide hydrogen peroxide and hypochlorous acid,
cannot be considered as free radicals, but have a powerful oxi-
dizing capacity, which further contributes to oxidative stress
within vascular tissues (Munzel et al., 2010). The main sources of
increased oxidative stress in cardiovascular diseases are the nicoti-
namide dinucleotide phosphate (NADPH) oxidase, the xanthine
oxidase, mitochondria and, under certain conditions, even eNOS
(Munzel et al., 2010).
Oxidative stress appears to stimulate central sympathetic out-
flow in various experimental models of hypertension, with little
or no effect in control animals (Shokoji et al., 2003; Campese
et al., 2005; Ye et al., 2006; Oliveira-Sales et al., 2008). Increased
oxidative stress has been documented in specific nuclei of the
brain involved in the regulation of sympathetic control of vaso-
motor tone in hypertensive but not normotensive rats (Kishi
et al., 2004; Tai et al., 2005). Injection of antioxidants directly
at this level results in a decrease in BP and SNA (Ye et al., 2006;
Oliveira-Sales et al., 2008). Superoxide could act by reducing NO
availability, in parallel in the central nervous system as well as
in the vasculature (Zucker, 2006), although some studies also
hypothesized an NO-independent effect (Xu et al., 2002).
Experimental studies have demonstrated that acute correction
of oxidative stress, with vitamin C (Oliveira-Sales et al., 2008) or
different antioxidants infused both intravenously and intracere-
brally (Xu et al., 2002; Shokoji et al., 2003; Campese et al., 2005),
can reduce SNS activity. Selective vitamin C injection in RVLM
of renovascular rats reproduces all hemodynamic and sympatho-
inhibitory effects of its systemic administration (Oliveira-Sales
et al., 2008). Moreover other experimental studies suggest that the
interaction between SNS and oxidative stress may occur not only
in the brain stem, but also in the peripheral nervous system, such
as preganglionic neurons (Lin et al., 2003), sympathetic ganglia
(Cao et al., 2007), peripheral nerves (Shokoji et al., 2004), and
neuroeffector junctions (Macarthur et al., 2008).
In recent decades the possible antihypertensive effect of
antioxidants has been investigated in several studies, with con-
flicting results (Duffy et al., 1999; Fotherby et al., 2000; Kim
et al., 2002; Ward et al., 2004; Hooper et al., 2008). This effect,
attributed in the past mainly to vascular mechanisms such as
restoration of NO-mediated vasodilation (Taddei et al., 1998;
Hooper et al., 2008), could be at least in part a consequence of
sympatho-inhibition achieved by antioxidants, as recently sug-
gested also in humans (Bruno et al., 2012a).
RENIN-ANGIOTENSIN SYSTEM
Angiotensin-II is able to potentiate SNS activity at different
levels (Grassi, 2001). In experimental studies intracerebral infu-
sion of angiotensin-II caused hypertension associated with sys-
temic vasoconstriction and a baroreflex reset towards higher
BP levels (Reid, 1992). It was first demonstrated that vascular
smooth muscle NADPH oxidase is activated by Angiotensin II
and subsequently increases vascular ROS levels (Griendling et al.,
1994). However, more recent work has shown that a similar
phenomenon occurs within the central nervous system, where
Angiotensin-II up-regulates NADPH oxidase via activation of
type 1 (AT1) receptors (Zucker, 2006). Importantly, this process
has been shown to occur in neuroanatomical areas implicated in
central sympathetic regulation such as the RVLM, the circumven-
tricular organs, and the paraventricular nuclei (Gao et al., 2005;
Li et al., 2006; Zucker, 2006). Zucker and colleagues have sug-
gested that this pathway becomes very important in heart failure
and contributes to the well-known reductions in arterial barore-
flex sensitivity and increases in central sympathetic drive present
in this disease state (Gao et al., 2005; Zucker, 2006). Overall, these
animal investigations indicate that increases in central sympa-
thetic outflow in heart failure are mediated via Angiotensin II
activation of NADPHoxidase and subsequent production of ROS,
whichmay directly activate central SNS pathways alongwith scav-
enging NO, thereby removing the tonic restraint on sympathetic
outflow (Fisher et al., 2009). Emerging evidence indicates that
both AT1 andAT2 receptors are involved in sympathetic discharge
regulation in the RVLM during heart failure (Gao et al., 2005,
2008).
Furthermore, at the peripheral level Angiotensin-II facili-
tates neuronal transmission within sympathetic ganglia (Reit,
1972; Reid, 1992), favors norepinephrine release by sympathetic
nerve terminals, acting on pre-synaptic receptors (Starke, 1977)
and enhances α-mediated vasoconstriction in arterioles (Grassi,
2001). The latter phenomenon was also demonstrated in humans
(Taddei et al., 1995; Saino et al., 1997).
ENDOTHELIN
Endothelin-1 (ET-1) is a vasoconstrictor and mitogenic peptide
produced by endothelial cells and its important role in regulation
of vascular tone and structure is well established (Dhaun et al.,
2008). Essential hypertension is characterized by increased ET-1
vasoconstrictor tone (Cardillo et al., 1999; Taddei et al., 1999),
which seems to be a consequence of reduced NO availability
(Taddei et al., 1999). The role of the ET system in cardiovascu-
lar homeostasis is not limited to its direct vascular effects, but
also involves the neural regulation of vasomotor tone (Mosqueda-
Garcia et al., 1993). Experimental evidence suggests that ET-1
can stimulate central and peripheral SNS activity through ETA
receptors (Gulati et al., 1997; Nakamura et al., 1999). While
intracerebral administration of ET-1 can increase BP and SNS
activity mainly through ETA receptors in hypertensive as well in
normotensive animals (Gulati et al., 1997; Nakamura et al., 1999),
the administration of an ETA receptor antagonist determines the
opposite effect only in hypertensive animals, suggesting a specific
sympathoexcitatory role for the endogenous ET system in this
condition (Nakamura et al., 1999). With regard to the peripheral
autonomic nervous system, ET-1 can act in carotid bodies and in
cervical superior and nodose ganglia, influencing baroreflex and
chemoreflex regulation. ET-1 is also released by post-ganglionic
sympathetic neurons, possibly modulating catecholamine release
and vascular tone, and stimulates catecholamine release from
adrenal glands (Mortensen, 1999).
ENDOTHELIAL FUNCTION AND SYMPATHETIC NERVOUS
SYSTEM ACTIVITY IN HUMANS: A CAUSE-EFFECT
RELATIONSHIP?
Reduced availability of NO in the vasculature is present in several
cardiovascular risk factors and diseases and leads to endothelial
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dysfunction, which is the first step of the atherosclerotic pro-
cess. Endothelial dysfunction is increasingly accepted as a com-
mon trait of essentially all cardiovascular risk factors. Impaired
endothelial homeostasis (mostly demonstrated under the form of
abnormal vasomotor responses) has been shown, among other
individuals, in the elderly, after chronic or acute smoking, in
patients with hypercholesterolemia or hypertriglyceridemia, in
patients with Type I and II diabetes mellitus, hypertension and
metabolic syndrome (Brunner et al., 2005) (Table 1). A number
of different techniques have been developed to assess endothe-
lial function in humans, including biochemical markers, genetic
markers, vascular reactivity tests: these methodological aspects
are reviewed in greater detail elsewhere (Deanfield et al., 2005).
This section will review the main advances in elucidating the
relationship between endothelial function and SNS activity in
humans, obtained by microneurographic recordings, allowing
direct quantification of MSNA.
EVIDENCE IN HEALTHY HUMANS
There is indirect evidence of a reciprocal relationship between
endothelial function and the activity of the SNS. Men tend to
have higher sympathetic outflow than women (Ng et al., 1993;
Narkiewicz et al., 2005), who in turn have higher endothelial
function, evaluated in the small resistance arteries as well as in
conduit arteries (Virdis and Taddei, 2012). Furthermore, vascular
aging and sympathetic traffic show similar behavior over time in
males and females (Ng et al., 1993; Narkiewicz et al., 2005; Virdis
and Taddei, 2012). Sympathetic nerve activity is augmented in the
early morning before waking, while endothelial function has been
reported to be attenuated (Somers et al., 1993; Otto et al., 2004).
Several studies explored the effects of basal NO release
on MSNA. Intravenous administration of NOS inhibitors in
Table 1 | Conditions/diseases characterized by both autonomic and
endothelial dysfunction and interventions known to ameliorate both
autonomic and endothelial dysfunction.
Conditions/diseases
characterized by both autonomic
and endothelial dysfunction
Interventions known to
ameliorate both autonomic and
endothelial dysfunction
Aging
Menopause
Hypertension
Obesity
Diabetes
Metabolic syndrome
Smoking
Obstructive sleep apnea syndrome
Ischemic heart disease
Heart failure
Chronic kidney disease
Pre-eclampsia
Chronic obstructive pulmonary
disease
Pulmonary artery hypertension
Hepatic cirrhosis
Hypothyroidism
Physical exercise
Weight loss
Estrogen replacement therapy
Renin-angiotensin system blockers
Endothelin antagonists
Antioxidants
Statins
Sibutramine
Central sympatholytic drugs
healthy humans initially appeared to have no effect on SNS
activity, evaluated by means of microneurography (Hansen et al.,
1994), while further studies suggested a sympathoexcitatory effect
(Owlya et al., 1997). This apparent contradiction was then
explained by the demonstration that different L-NMMA dosages
exerted different effects on humans. Lepori and coauthors (Lepori
et al., 1998) administered intravenously increasing L-NMMA
dosages, and equipressor phenylephrine dosages, in healthy vol-
unteers. High L-NMMA doses suppressed MSNA to a similar
extent as phenylephrine. In contrast, low L-NMMAdoses induced
no changes in MSNA, even in the presence of a significant BP
increase. When a vasodilator, such as sodium nitroprusside, was
co-infused with L-NMMA in order to avoid any BP modifica-
tions, an increase in MSNA was evident (Owlya et al., 1997).
Taken together, these data suggest that L-NMMA infusion at high
doses causes mainly direct peripheral vasoconstriction, while low
doses were able to reveal an excitatory effect on SNS, demonstrat-
ing that in physiological conditions NO can modulate vascular
tone both at the neuronal and endothelial level. In particular,
NO seems to act in the central nervous system by influencing
tonic sympathetic discharge, without influencing the efficacy of
reflex responses. Thus, during intravenous L-NMMA infusion,
MSNA changes during pharmacological baroreceptor activation
and deactivation (Miyano et al., 1997), as well as during tilt
test maneuvers (Cui et al., 2003), lower-body negative pressure
(Spieker et al., 2000), and handgrip test (Owlya et al., 1997), were
preserved. In contrast, L-NMMA infusion blunted hyperten-
sive and sympathoexcitatory responses to mental stress, through
unknown mechanisms (Lindqvist et al., 2004). Baroreceptor reg-
ulation of heart rate during lower-body negative pressure was
also altered after inhibition of NO synthesis in healthy volun-
teers, suggesting an important role of NO in heart rate regulation
in humans (Spieker et al., 2000). Interestingly, altered barore-
flex regulation of heart rate, but not of MSNA, is a typical
feature of endothelial dysfunction-related states, such as arte-
rial hypertension (Grassi et al., 1998), a condition mimicked by
NOS-inhibition.
Interaction between NO and SNS in humans seem to occur not
only in the central nervous system, but also at the peripheral level.
In subjects undergoing thoracic sympathectomy for hyperhidro-
sis, vasoconstriction to intravenous L-NMMA administration is
potentiated (Lepori et al., 1998), suggesting that sympathetic
innervation is physiologically able to inhibit vasoconstriction
induced by NOS-inhibition.
Some authors suggested that interaction between NO and
SNS could explain, at least in part, large interindividual dif-
ferences in resting MSNA among normotensive humans with
similar BP, thus elucidating the role of SNS in long-term con-
trol of BP (Skarphedinsson et al., 1997; Charkoudian et al.,
2006; Joyner et al., 2008). Skarphedinsson and coauthors found
a significant positive correlation between plasma nitrates and
resting MSNA in 22 healthy young volunteers. This led to the
hypothesis that greater basal NO vascular tone could counter-
act excessive vasoconstriction induced by adrenergic overactivity,
resulting in similar BP values with different sympathetic discharge
levels (Skarphedinsson et al., 1997). Charkoudian and coauthors
recently implemented this hypothesis, introducing cardiac output
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as a cofactor. In this study L-NMMA was infused intravenously
in 18 healthy normotensive volunteers with resting MSNA vary-
ing from 13 to 68 bursts/100 heartbeats. In subjects with high
resting MSNA, L-NMMA administration induced an almost
twofold increase in BP as compared to those with low MSNA
(Charkoudian et al., 2006). This effect was not associated with
similar increase in total peripheral resistances, indicating similar
vasoconstriction, but with different cardiac output. In particular,
subjects with high MSNA had lower resting cardiac output, and
a lower decrease in cardiac output during L-NMMA administra-
tion (Charkoudian et al., 2006). Moreover cardiac output, which
is a key determinant of resting BP together with sympathetic tone
(Charkoudian et al., 2006), is also NO-dependent, since it was
decreased after NOS-inhibition (Spieker et al., 2000). Thus, it is
conceivable that in pathological conditions in which NO basal
vascular tone is altered, subjects with higher baselineMSNA could
be at greater risk of developing hypertension.
Very recently, an inverse relationship between markers of
endothelial function and of sympathetic activity in healthy con-
ditions has been suggested. In a group of 314 healthy subjects
endothelial function in the brachial artery was inversely related to
plasma norepinephrine concentration (Kaplon et al., 2011). The
above-mentioned correlation was significant in women but not in
men even after controlling for age, common cardiovascular risk
factors and oxidative stress, suggesting that sympathetic activ-
ity could be a gender-specific determinant of vascular function
(Kaplon et al., 2011). In the cited study, conduit artery endothelial
function wasmeasured bymeans of a non-invasive brachial artery
reactivity test known as flow-mediated dilation (FMD), in which
NO release is stimulated by post-ischemic reactive hyperemia,
and the measured endpoint is constituted by the percent change
in brachial artery diameter, obtained by ultrasound (Deanfield
et al., 2005; Thijssen et al., 2011). FMD is one of the most widely
used techniques of endothelial function assessment, and a recent
meta-analysis demonstrated that it is an independent predictor
of cardiovascular events in the general population as well as in
subjects with cardiovascular risk factors or disease (Inaba et al.,
2010). The correlation between markers of endothelial function
and SNS activity was also demonstrated in one microneuro-
graphic study (Sverrisdottir et al., 2010). In a group of ten healthy
volunteers, with age ranging from 24 to 61 years, MSNA was
inversely related to reactive hyperemia index, obtained by fin-
ger photoplethysmography (Sverrisdottir et al., 2010) (Figure 2).
The device records pulse wave amplitude at baseline and during
reactive hyperemia following arm arterial occlusion. The reac-
tive hyperemia index is a non-invasive index of microvascular
endothelial function. Its association with classical cardiovascu-
lar risk factors was validated in large cohorts but its prognostic
role is yet to be established (Reriani et al., 2010). The relationship
between MSNA and reactive hyperemia index was independent of
age and sex, but related to habitual physical activity (Sverrisdottir
et al., 2010).
Physical activity has been demonstrated to be protective
against the development of cardiovascular events. The mecha-
nisms involved include reduction of sympathetic outflow and
restoration of endothelial function (Cornelissen and Fagard,
2005; Mora et al., 2007). A metaanalysis of clinical trials reported
FIGURE 2 | Inverse relationship between muscle sympathetic nerve
activity (MSNA) expressed as burst frequency (bursts/min) and
reactive hyperemic index (%) in 10 healthy controls, (r = 0.8,
p = 0.005). (From Sverrisdottir et al., 2010, CC-BY license).
that the effects of exercise training on BP, driven by peripheral
vascular resistance reduction, are accompanied by reduction in
heart rate and norephinephrine levels (Cornelissen and Fagard,
2005). These data based on non-invasive and indirect parameters
were confirmed in smaller studies using direct neural record-
ings by microneurography. In hypertensive patients, a program of
exercise training consisting of three 60min exercise sessions per
week for 4 months reduced BP and MSNA and restored barore-
flex sensitivity (Laterza et al., 2007). Exercise training is known to
ameliorate endothelial dysfunction in healthy subjects (Clarkson
et al., 1999), as well as in the presence of well known risk fac-
tors (Higashi et al., 1999; Taddei et al., 2000; Franzoni et al.,
2005) and established cardiovascular diseases (Hornig et al., 1996;
Hambrecht et al., 2003). To date, it is not clear whether physi-
cal activity acts by inducing sympatho-inhibition and restoration
of vascular function in parallel, or rather influences the one by
means of the other. This important aspect needs to be elucidated
in further studies.
ENDOTHELIAL FUNCTION DURING SYMPATHO-EXCITATORY
MANEUVERS
One-Way to investigate the relationship between sympathetic
vasoconstrictor activity and NO formation is to measure
markers of endothelial function during maneuvers known
to increase sympathetic nerve traffic. However, this indi-
rect approach has achieved conflicting results. In 16 young,
healthy volunteers, brachial artery FMD was measured in
resting conditions and during lower-body negative pressure
(Hijmering et al., 2002). FMD, but not vasodilation to nitrates
(which is endothelium-independent), was markedly reduced
by this baroreceptor-unloading maneuver. Furthermore, vascu-
lar response during lower-body negative pressure was blunted
by phentolamine infusion, which in turn had no effect on
resting FMD (Hijmering et al., 2002). In contrast, in young
healthy volunteers, FMD in the femoral artery was not modified
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by sympathetic activation, obtained by cold pressor test, a
potent non-baroreflex sympathoexcitatory stimulus (Victor et al.,
1987), or deactivation, obtained after maximal cycling exercise,
whereas this did occur in older healthy subjects (Thijssen et al.,
2006). Mental stress is a powerful stimulus for MSNA increase
(Anderson et al., 1987; Hjemdahl et al., 1989), possibly as a result
of a primary central sympathetic excitation (Wallin et al., 1992).
Acute mental stress also induces transient but sustained endothe-
lial dysfunction, lasting up to 4 h, accompanied by BP, heart rate,
and salivary cortisol increase (Ghiadoni et al., 2000). This long-
lasting effect was prevented by selective endothelin-A receptor
antagonism (Spieker et al., 2002), which was demonstrated to
achieve sympatho-inhibition (Bruno et al., 2011).
A possible mechanism explaining discrepancies in endothelial
function behavior during different sympatho-excitatory maneu-
vers was suggested in a recent study (Padilla et al., 2010). Fourteen
young healthymen performed three sympatho-excitatory maneu-
vers: graded lower body negative pressure, cold pressor test,
and 35% maximal voluntary contraction handgrip followed by
post-exercise ischemia. Lower body negative pressure, a neutral
maneuver as far as BP is concerned, induced a proportional
increase in MSNA and oscillatory/retrograde shear stress. During
the cold pressor test and handgrip, on the other hand, the con-
comitant hypertensive effect probably masked this phenomenon,
which is able to cause endothelial dysfunction in conduit arteries
(Padilla et al., 2010). Thus, further microneurographic stud-
ies, allowing continuous recordings during acute challenges and
simultaneous vascular acquisitions, could help to elucidate the
acute effect of SNS activation on vascular function, clarifying
apparently contrasting findings. A more detailed study of phys-
iological behavior during acute sympathoexcitatory maneuvers
could suggest pathways involved in chronic autonomic disregu-
lation in cardiovascular diseases.
EVIDENCE IN DISEASES CHARACTERIZED BOTH BY ENDOTHELIAL
DYSFUNCTION AND INCREASED SYMPATHETIC NERVE TRAFFIC
Another appropriate way to investigate the relationship between
vasoconstrictor nerve activity and NO formation would be to
study states of chronically increased sympathetic nerve traffic.
Virtually all cardiovascular risk factors and diseases in which
increased adrenergic drive was demonstrated, including hyper-
tension (Grassi et al., 1998), obesity (Grassi et al., 2004), chronic
kidney disease (Ligtenberg et al., 1999), heart failure (Grassi
et al., 1995), are also characterized by endothelial dysfunction
(Brunner et al., 2005), as well as many other cardiovascular
and non-cardiovascular diseases (Table 1), Furthermore, sev-
eral pharmacological and non-pharmacological interventions are
known to ameliorate both autonomic and vascular dysfunction
(Table 1). Up to now, few studies have directly investigated pos-
sible interrelationships between SNS and vascular function in
disease conditions.
In essential hypertension, increased SNS activity is one of
the main mechanisms responsible for the pathogenesis of the
disease and the development of target organ damage (Grassi
et al., 1998; Grassi, 2009). Studies performed by using direct as
well as indirect approaches to assess neuroadrenergic function
have almost univocally shown that the sympathetic overdrive is
detectable not only in borderline but also in mild to moderate
and in more severe essential hypertensive patients, varyingin
parallel with the magnitude of the BP increase. Increased sym-
pathetic discharge is peculiar to the essential hypertensive state
and involves each district studied (muscle, brain, kidney, heart),
except the skin district (Grassi et al., 1998; Grassi, 2009).
Although several studies support the hypothesis that increased
sympathetic discharge originates mainly in the central nervous
system (Ferrier et al., 1992), it is also true that human hyperten-
sion is characterized at the peripheral level by down-regulation
of peripheral α-adrenergic receptors, impairment in the neu-
ronal reuptake of norepinephrine from sympathetic nerve ter-
minals, and altered functional interaction at the level of the
vascular wall between norepinephrine, epinephrine, and other
humoral (such as angiotensin II), metabolic (including insulin
and leptin), or endothelium-derived substances (Grassi, 2009).
However, the mechanisms underlying such alterations are not
yet fully understood. Another pathophysiological characteristic of
essential hypertension is the presence of endothelial dysfunction,
demonstrated at the coronary and peripheral level, in the micro-
and macrocirculation (Versari et al., 2009). Reduced NO avail-
ability, which is at the basis of endothelial dysfunction, is mainly
caused by increased vascular oxidative stress (Taddei et al., 1998),
but ET-1 and other endothelium-derived contracting factors are
also involved (Versari et al., 2009).
Up to now, only few preliminary studies have investigated the
NO-SNS relationship in hypertensive patients. Gamboa and col-
leagues set up an elegant experimental protocol (evaluation of BP
responses to L-NMMA infusion during ganglionic blockade) in
order to ascertain the contribution of basal NO tone in BP reg-
ulation independently of interaction with SNS, in physiological
and pathological states in humans. They found that NO tonically
restrains BP by about 30mmHg, with no differences between nor-
motensive, pre-hypertensive and hypertensive patients (Gamboa
et al., 2012). The authors concluded that if NO deficiency con-
tributes to hypertension, it is likely to be due to interactions with
the autonomic nervous system, which were excluded in the study
(Gamboa et al., 2012). However, this indirect suggestion needs to
be confirmed in other studies.
Similarly, despite the growing body of evidence from experi-
mental studies, few data are available on the systemic interaction
between endogenous ET-1 and SNS in humans either in physio-
logical or pathological conditions. Interestingly, local infusion of
ET-1 is able to potentiate SNS-mediated vasoconstriction induced
by deep breath (Haynes et al., 1994). We recently demonstrated
that ET-1 likewise modulates sympathetic activity in humans
through ETA receptors, and that this interaction is peculiar to the
hypertensive status (Bruno et al., 2011). In 15 untreated patients
with essential hypertension and in 10 healthy subjects MSNA
was recorded in resting conditions and during acute intravenous
infusion of BQ123, an ETA–receptor antagonist. BQ123 induced
BP decrease in hypertensive and normotensive subjects, accom-
panied by a blunted increase in SNS activity (Figure 3). This
finding suggests that endogenous ET-1, by the stimulation of ETA
receptors, contributes to the basal sympathetic tone that con-
trols vascular resistances in humans. Moreover in hypertensive
subjects as compared to the control group, lower doses of BQ123
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FIGURE 3 | Behavior of systolic BP and MSNA in hypertensive
patients and normotensive subjects during BQ123 (an endothelin-A
receptor antagonist) infusion at 0.1mg/kg per hour (black circles)
and 0.2mg/kg per hour (gray circles), as well as during sodium
nitroprusside (white circles) infusion at equidepressor doses.
Data are shown as mean ± SEM. b/100hb: bursts per 100hb; ∗P0.05 vs.
baseline; †P0.05 vs. sodium nitroprusside. (From Bruno et al., 2011, with
permission).
were sufficient to reveal the vasodilating and sympatho-inhibitory
effect of ETA blockade. Suggesting that essential hypertension
is characterized by a greater susceptibility to the sympatho-
excitatory effect of endogenous ET-1 through activation of the
ETA receptor subtype (Bruno et al., 2011). Taken together, these
findings suggest that in the presence of essential hypertension, the
increased biological activity of endogenous ET-1 takes place in
parallel in different systems, such as in the peripheral vasculature
and in the SNS.
Very recently interactions between the oxidative stress sys-
tem and SNS were investigated in a microneurographic study
enrolling 32 essential hypertensive patients and 22 healthy volun-
teers (Bruno et al., 2012a). In this study high dose Vitamin C infu-
sion significantly lowered BP and MSNA in hypertensive patients
but not in normotensive subjects. Sympatho-vagal balance and
spontaneous baroreflex sensitivity were restored during vitamin
C infusion in hypertensive subjects but not in healthy subjects.
These results demonstrated that acute administration of vitamin
C is able to reduce cardiovascular adrenergic drive in hypertensive
patients, suggesting that oxidative stress is involved in the regula-
tion of sympathetic activity in essential hypertension. In contrast,
this pathophysiological mechanism is not present in healthy con-
ditions (Bruno et al., 2012a), as also suggested by previous studies
(Bell et al., 2003).
Sympathetic activation is a feature of chronic kidney dis-
ease both in early and advanced stages (Converse et al., 1992;
Grassi et al., 2011a), representing one of the most powerful pre-
dictors of mortality and cardiovascular events (Zoccali et al.,
2002). Increased neuroadrenergic drive is independent of circu-
lating uremia related toxins and probably related to afferent nerve
signals from ischemic kidneys, decrease in NO bioavailability,
stimulation of carotid chemoreceptors by metabolic acidosis and
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activation of the renin-angiotensin system (Kotanko, 2006). The
endothelium-SNS relationship was explored in 48 patients with
chronic kidney disease of different etiologies (Grassi et al., 2011b).
In this population, the tertile with highest sympathetic nerve traf-
fic values also showed the highest ADMA levels, and this associa-
tion was paralleled by a continuous, positive relationship between
these two parameters, independently of other confounders. Both
sympathetic nerve traffic and ADMA were inversely related to
the estimated glomerular filtration rate and directly related to left
ventricular geometry (Figure 4).
Remarkably, in a multiple regression model including both
variables, variance of the estimated glomerular filtration rate,
proteinuria, and left ventricular geometry explained by sym-
pathetic nerve traffic and ADMA largely overlapped, because
sympathetic nerve traffic but not ADMA was retained as signif-
icant (Grassi et al., 2011b). These results suggest that in chronic
kidney disease the relationship between sympathetic activity
and vascular function can be of crucial importance for pro-
gression of renal damage. This hypothesis is confirmed in a
prospective study involving 224 hemodialysis patients followed
up for about 3.5 years (Mallamaci et al., 2004). In this cohort
plasma norepinephrine and ADMA were both predictors of
death and cardiovascular events, and their prognostic significance
largely overlapped (Mallamaci et al., 2004). Moreover, systemic
intravenous infusion of ADMA increased renal SNA in rats
(Augustyniak et al., 2006), suggesting that in conditions in which
ADMA concentrations are elevated, NO-mediated regulation of
central sympathetic outflow could be impaired. Recent observa-
tions showed that the renal function decline over time in non-
proteinuric nephropathy-like hypertensive nephrosclerosis was
accelerated by adrenergic genetic influences (Chen et al., 2010),
and that angiotensin-converting enzyme inhibition, an interven-
tion that markedly inhibits the SNS in CKD patients (Ligtenberg
et al., 1999), determined a parallel decline in proteinuria and
ADMA levels in patients with diabetic nephropathy and preserved
glomerular filtration rate (Yilmaz et al., 2010).
There is some evidence that anxiety disorders are associated
with an increased cardiovascular risk (Fleet et al., 2000) and
the pathophysiology could be linked to autonomic alterations.
Whole-body and regional sympathetic nervous activity are not
elevated at rest, nor during mental stress, in patients with panic
disorder. On the other hand, epinephrine spillover from the heart
at rest is increased, while quantification from single vasoconstric-
tor unit recording provided evidence of a disturbed resting sym-
pathetic firing pattern in patients with panic disorder (Lambert
et al., 2006). Moreover, patients with panic disorder exhibited a
FIGURE 4 | Relationships between muscle sympathetic nerve activity (MSNA), asymmetric dimethylarginine (ADMA), and estimated GFR (eGFR) or
proteinuria in 48 stage 2–4 CKD patients (From Grassi et al., 2011b, with permission).
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loss in heart rate variability (Gorman and Sloan, 2000) and an
enhanced reflex gain of the arterial baroreflex control of MSNA
but no change in cardiac baroreflex sensitivity (Lambert et al.,
2002). Anxiety was also shown to be associated with endothelial
dysfunction via autonomic dysregulation, evaluated by spectral
analysis of heart rate variability in 41 subjects (Narita et al.,
2007). A recent study investigated the single-fiber and multi-fiber
pattern of muscle sympathetic firing in 8 women and 17 men
with metabolic syndrome and high BP (Lambert et al., 2010).
Women had higher cholesterol levels, higher depressive symp-
tom scores and similar multiunit MSNA compared with men,
but displayed a disturbed firing pattern of sympathetic activity
as indicated by a higher incidence of multiple spikes per burst.
Multiple firing during a sympathetic neural burst was associated
with higher trait anxiety score and higher affective depressive
symptoms (Lambert et al., 2010). Since gender plays a crucial role
in the association between metabolic syndrome and vascular dys-
function (Plantinga et al., 2008), these data reinforce the role of
gender-specific interaction between vascular function and SNS in
explaining the link between anxiety and cardiovascular risk.
In conclusion, several diseases are characterized by both
endothelial dysfunction and sympathetic traffic (Table 1).
However, a direct relationship between these two alterations has
so far been demonstrated in few conditions. Future research
should investigate this aspect in other diseases, such as obesity,
obstructive sleep apnea, heart failure, and many others. In par-
ticular, future studies should clarify the presence of a cause-effect
relationship, or of common causative mechanisms. Involvement
of different pathways underlying sympathetic/vascular activation
in different diseases may lead to specific treatment strategies.
ARTERIAL STIFFNESS AND SYMPATHETIC NERVE TRAFFIC
The two main functions of the arteries, namely the conduit
function (to deliver an adequate supply of blood to peripheral
tissues) and the cushioning function (to buffer pressure oscilla-
tions due to intermittent ventricular ejection), are closely related
to arterial elastic properties, which permit the generation and
propagation of a BP wave along the arterial walls (Nichols and
O’Rourke, 2005). At the level of bifurcations and areas of tur-
bulence, the pulse wave is reflected and retrograde waves are
generated, which, summed with the forward wave generated by
ventricular ejection, constitute the effective BP curve, contribut-
ing to the amplitude of pulse pressure and systolic BP (Nichols
and O’Rourke, 2005). The velocity of pulse wave propagation
is inversely related to large artery distensibility; this variable,
the so-called pulse wave velocity (PWV), as well as timing and
magnitude of wave reflection (expressed as the augmentation
index) can now be measured easily and non-invasively, becom-
ing probably the most widely used technique for assessment of
vascular function and structure (Laurent et al., 2006). The ageing
process is characterized by arteriosclerosis, a profound remod-
eling of arterial walls, associated with structural changes such
as increased collagen deposition and rupture of elastin fibers
in the vascular wall (Safar et al., 2003; Nichols and O’Rourke,
2005). Systemic arterial stiffness reflects the overall opposition
of large arteries to the pulsatile effects of ventricular ejection.
The consequences are increased left ventricular afterload with left
ventricular hypertrophy, reduced coronary perfusion with aggra-
vation of ischemia and progressive atherosclerosis (Ghiadoni
et al., 2009). As well as aging, several chronic disease states such as
hypertension diabetes, hypercholesterolemia, obesity, metabolic
syndrome, are associated with increased arterial stiffness (Laurent
et al., 2006). Both aortic PWV and the augmentation index
proved to be independent predictors of cardiovascular events in
a recent metaanalysis (Vlachopoulos et al., 2010).
In addition to structural changes, arterial stiffness is strongly
affected by vascular smooth muscle cell tone, which is in
turn regulated both by endothelial cell signaling and the SNS
(Wilkinson and McEniery, 2004). Sympathetic stimulation may
influence arterial wall mechanics both indirectly, by passively
increasing arterial pressure, or directly, by changing smooth mus-
cle cell tone (Boutouyrie et al., 1994; Joannides et al., 1995;
Lydakis et al., 2008). Boutouyrie and coauthors demonstrated
that radial artery diameter decreased during sympathoexcita-
tory maneuvers such as cold pressor and mental stress tests
(Boutouyrie et al., 1994), while other studies found a decrease
in radial artery stiffness during the cold pressor test (Joannides
et al., 1995). Conversely, in 13 young healthy subjects, wave reflec-
tion parameters exhibited different behavior during static exercise
or lower body negative pressure, with timing of reflected wave
and PP amplification being increased during the former and
unchanged during the latter (Lydakis et al., 2008). The authors
concluded that central arterial wall hemodynamics is linked to BP
changes rather than sympathetic tone per se (Lydakis et al., 2008).
On the other hand, acute withdrawal of sympathetic tone
caused increased large artery elasticity, as demonstrated in sym-
pathectomized rats (Mangoni et al., 1997), but also in healthy and
atherosclerotic subjects during brachial plexus or subarachnoid
anaesthesia or one month after removal of the lumbar sympa-
thectomy chain (Failla et al., 1999). Endothelium-derived factors
such as NO (Wilkinson et al., 2002) and ET-1 (McEniery et al.,
2003) have been proposed as physiological modulators of arterial
stiffness in healthy individuals. An inverse correlation between
endothelial dysfunction and arterial stiffness has been reported in
cross-sectional studies performed in healthy subjects, with con-
flicting results (McEniery et al., 2006; Koivistoinen et al., 2012),
as well as in patients with cardiovascular risk factors such as dia-
betes (Bruno et al., 2012b). In contrast, in healthy volunteers, the
reduction in brachial artery distensibility elicited by lower body
negative pressure and a cold pressor test was not influenced by
administration of exogenous NO-donors (Salzer et al., 2008).
Taken together, these studies suggest that the relationship
between arterial stiffness and sympathetic nerve traffic could be
mediated by endothelium-related mechanisms. However, the evi-
dence in this field is far from being conclusive and mechanistic
studies are still required.
In 16 healthy subjects, neither brachial artery distensibility
nor carotid artery distensibility were related to MSNA (Kosch
et al., 2002). Conversely, in 25 healthy male subjects multiple
linear regression analysis revealed that MSNA was an indepen-
dent determinant of carotid to femoral PWV (Swierblewska et al.,
2010). Given the paucity of data on this topic, it is not possible
to ascertain reasons for these discrepant results. However, the
different districts examined in the two studies, as well as gender
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differences in the study population, may be important factors to
take into account. The latter hypothesis is reinforced by a recent
study by Casey and coauthors (Casey et al., 2011). This study
shows for the first time a gender-specific relationship between
augmentation index and sympathetic vascular tone in healthy
humans. This finding is of particular interest since it provides an
explanation for better cardiovascular outcomes in women, who
appear to be protected from negative effects of sympathetic acti-
vation on arterial hemodynamics. The authors recruited 44 young
healthy subjects who underwent microneurography and appla-
nation tonometry to obtain wave reflection parameters. MSNA
was directly related to the augmentation index and total periph-
eral resistances in men while, interestingly, the relation between
MSNA and augmentation index was inverse in women. Thus,
the authors hypothesized that MSNA is able to compromise wave
reflection, which is a negative prognostic factor for cardiovascular
disease, only in men (Casey et al., 2011). However, further phys-
iopathological studies are required to explore the mechanisms
responsible for this gender-specific phenomenon.
Not only acute perturbations of SNS activity, as described
above, can influence vascular stiffness, but chronic alterations
of sympathetic discharge may also have a trophic effect on
the vascular wall, increasing arterial stiffness (Bruijns et al.,
1998). Consistent with the latter hypothesis, some animal studies
showed a reduction in arterial distensibility in long-term sym-
pathectomized rats (Lacolley et al., 1995). This hypothesis could
additionally be tested in diseases characterized by chronically
increased sympathetic traffic. However, to our knowledge, only
one study investigating the relationship between arterial stiffness
and adrenergic drive in this setting has been published (Kosch
et al., 2002). In renal transplant recipients, who showed both
a major impairment of large artery elastic wall properties and
sympathetic overactivity, a relationship was found between sym-
pathetic activity, measured bymicroneurography, and large artery
distensibility, in muscular arteries, such as the brachial artery,
but not in elastic arteries such as the carotid artery (Kosch et al.,
2002). The correlation between brachial artery distensibility and
MSNA remained statistically significant independently of arterial
diameter, BP, graft function, sex, body mass index and smoking
habits (Kosch et al., 2002). However, aortic stiffness in end stage
renal disease displays a different pathophysiology and anatom-
ical substrate as compared to other morbid conditions. Thus,
the main muscular arterial involvement in the relationship with
MSNA is not surprising.
Finally, is it important to notice that the relation between arte-
rial stiffness and sympathetic activity appears to be bidirectional.
Large artery stiffness can interfere with autonomic regulation by
impairing carotid baroreflex sensitivity (Chapleau et al., 1995).
This hypothesis was demonstrated for cardiovagal baroreflex sen-
sitivity (Mattace-Raso et al., 2007) and recently confirmed also
for sympathetic baroreflex sensitivity in a study using microneu-
rography for quantification of adrenergic drive and ultrasound
and magnetic resonance for evaluation of carotid and aortic
distensibility in 61 elderly subjects (Okada et al., 2012).
CONCLUSIONS
A crucial role of SNS in regulation of vascular function, in
addition to the reflex regulation of vasomotor tone, is sug-
gested by several lines of evidence. First, the same pathways are
involved in central and peripheral autonomic regulation as well
as in vascular function regulation: NO, ROS, ET, and the renin-
angiotensin system. Second, markers of vascular dysfunction
are inversely related to quantification of sympathetic discharge.
Third, sympatho-excitatory maneuvers impair endothelial func-
tion. Fourth, several cardiovascular diseases are characterized by
vascular dysfunction as well as sympathetic overactivity. However,
there is still a paucity of data in humans on common regulat-
ing pathways. Furthermore, so far the studies demonstrating an
association between vascular dysfunction and sympathetic acti-
vation evaluated mainly surrogate markers and enrolled very
small cohorts. The physiopathology of sympathetic regulation of
vascular function in cardiovascular diseases, almost completely
unexplored at the moment, appears to be an intriguing field
of research, with possible implications for treatment of these
conditions.
In conclusion, although microneurographic recordings have
allowed great advances in knowledge of mechanisms involved
in sympathetic regulation of vascular function, this field is still
largely unexplored in humans, both in physiological and patho-
logical conditions.
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